Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Editorial

Lipid Guidelines and Cardiovascular Prevention: Let’s Manage the Risk of Our Patients!

Author(s): Manfredi Rizzo*

Volume 29, Issue 6, 2023

Published on: 24 February, 2023

Page: [466 - 467] Pages: 2

DOI: 10.2174/1381612829666230220121711

Price: $65

conference banner
« Previous Next »
[1]
Cybulska B, Kłosiewicz-Latoszek L, Penson PE, Nabavi SM, Lavie CJ, Banach M. How much should LDL cholesterol be lowered in secondary prevention? Clinical efficacy and safety in the era of PCSK9 inhibitors. Prog Cardiovasc Dis 2021; 67: 65-74.
[http://dx.doi.org/10.1016/j.pcad.2020.12.008] [PMID: 33383060]
[2]
Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis 2019; 290: 140-205.
[http://dx.doi.org/10.1016/j.atherosclerosis.2019.08.014] [PMID: 31591002]
[3]
Vrablik M, Seifert B, Parkhomenko A, et al. Lipid-lowering therapy use in primary and secondary care in Central and Eastern Europe: DA VINCI observational study. Atherosclerosis 2021; 334: 66-75.
[http://dx.doi.org/10.1016/j.atherosclerosis.2021.08.035] [PMID: 34482090]
[4]
Zeitouni M, Sabouret P, Kerneis M, et al. 2019 ESC/EAS Guidelines for management of dyslipidaemia: Strengths and limitations. Eur Heart J Cardiovasc Pharmacother 2021; 7(4): 324-33.
[http://dx.doi.org/10.1093/ehjcvp/pvaa077] [PMID: 32652000]
[5]
Vekic J, Zeljkovic A, Al Rasadi K, et al. A new look at novel cardiovascular risk biomarkers: The role of atherogenic lipoproteins and innovative antidiabetic therapies. Metabolites 2022; 12(2): 108.
[http://dx.doi.org/10.3390/metabo12020108] [PMID: 35208183]
[6]
Fonseca L, Paredes S, Ramos H, Oliveira JC, Palma I. Apolipoprotein B and non-high-density lipoprotein cholesterol reveal a high atherogenicity in individuals with type 2 diabetes and controlled low-density lipoprotein-cholesterol. Lipids Health Dis 2020; 19(1): 127.
[http://dx.doi.org/10.1186/s12944-020-01292-w] [PMID: 32505210]
[7]
Tribble DL, Rizzo M, Chait A, Lewis DM, Blanche PJ, Krauss RM. Enhanced oxidative susceptibility and reduced antioxidant content of metabolic precursors of small, dense low-density lipoproteins. Am J Med 2001; 110(2): 103-10.
[http://dx.doi.org/10.1016/S0002-9343(00)00700-2] [PMID: 11165551]
[8]
Vekic J, Zeljkovic A, Stefanovic A, et al. Novel pharmaceutical and nutraceutical-based approaches for cardiovascular diseases prevention targeting atherogenic small dense LDL. Pharmaceutics 2022; 14(4): 825.
[http://dx.doi.org/10.3390/pharmaceutics14040825] [PMID: 35456658]
[9]
Patti AM, Giglio RV, Papanas N, Rizzo M, Rizvi AA. Future perspectives of the pharmacological management of diabetic dyslipidemia. Expert Rev Clin Pharmacol 2019; 12(2): 129-43.
[http://dx.doi.org/10.1080/17512433.2019.1567328] [PMID: 30644763]
[10]
Banach M, Rizzo M, Obradovic M, et al. PCSK9 inhibition - a novel mechanism to treat lipid disorders? Curr Pharm Des 2013; 19(21): 3869-77.
[http://dx.doi.org/10.2174/13816128113199990303] [PMID: 23286435]
[11]
Sahebkar A, Serban MC, Mikhailidis DP, et al. Head-to-head comparison of statins versus fibrates in reducing plasma fibrinogen concentrations: A systematic review and meta-analysis. Pharmacol Res 2016; 103: 236-52.
[http://dx.doi.org/10.1016/j.phrs.2015.12.001] [PMID: 26657419]
[12]
Fogacci F, Banach M, Mikhailidis DP, et al. Safety of red yeast rice supplementation: A systematic review and meta-analysis of randomized controlled trials. Pharmacol Res 2019; 143: 1-16.
[http://dx.doi.org/10.1016/j.phrs.2019.02.028] [PMID: 30844537]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy